Hanmi Pharm (KRX: 128940)
Who is buying Hanmi Pharm?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net sold ₩116.3bn ($87M) of Hanmi Pharm, the 23rd largest foreign net sale among 832 KOSPI stocks. Institutions net bought ₩128.3bn ($96M) and retail investors net sold ₩10.4bn ($8M) over the same window. Foreigners were net buyers on 7 of the 20 sessions.
Foreign investors hold 11.66% of Hanmi Pharm's listed shares (KRX ownership data as of Oct 13, 2026), down from 13.7% twenty sessions earlier and 13.64% a year ago.
The stock closed at ₩453,000 on Oct 13, 2026: -8.39% over 20 sessions, +0.22% year-to-date, +29.80% over one year. The 52-week range is ₩302,000 – ₩647,000.
At ₩453,000 the stock trades at 25.72× 12-month-forward consensus earnings (9 analysts), 26.06× on FY2027 estimates. The trailing P/E published by KRX is 33.88×, based on the last completed fiscal year.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩453,000 | +₩15.8bn | ₩-3.7bn | ₩-12.0bn |
| 2026-10-12 | ₩474,500 | +₩4.5bn | +₩4.1bn | ₩-8.9bn |
| 2026-10-08 | ₩480,500 | ₩-71.3bn | +₩1.8bn | +₩70.0bn |
| 2026-10-07 | ₩534,000 | ₩-13.4bn | ₩-4.0bn | +₩16.8bn |
| 2026-10-06 | ₩523,000 | +₩5.6bn | ₩-0.2bn | ₩-6.3bn |
| 2026-10-02 | ₩506,000 | ₩-0.0bn | +₩0.9bn | ₩-0.4bn |
| 2026-10-01 | ₩497,500 | ₩-2.3bn | +₩0.8bn | +₩1.4bn |
| 2026-09-30 | ₩499,000 | +₩5.9bn | +₩0.3bn | ₩-6.2bn |
| 2026-09-29 | ₩507,000 | +₩2.9bn | ₩-1.2bn | ₩-1.8bn |
| 2026-09-28 | ₩504,000 | ₩-7.3bn | ₩-2.3bn | +₩11.0bn |
| 2026-09-23 | ₩520,000 | +₩8.9bn | +₩11.1bn | ₩-21.2bn |
| 2026-09-22 | ₩502,000 | +₩5.5bn | ₩-2.2bn | ₩-3.0bn |
| 2026-09-21 | ₩505,000 | ₩-2.7bn | +₩6.1bn | ₩-3.5bn |
| 2026-09-18 | ₩503,000 | ₩-16.2bn | +₩6.6bn | +₩9.7bn |
| 2026-09-17 | ₩515,000 | ₩-13.7bn | +₩32.6bn | ₩-19.6bn |
| 2026-09-16 | ₩502,000 | ₩-24.0bn | +₩39.4bn | ₩-13.6bn |
| 2026-09-15 | ₩496,500 | ₩-12.7bn | +₩30.8bn | ₩-16.8bn |
| 2026-09-14 | ₩474,000 | ₩-0.9bn | +₩14.2bn | ₩-13.6bn |
| 2026-09-11 | ₩464,000 | ₩-0.3bn | ₩-6.9bn | +₩7.2bn |
| 2026-09-10 | ₩481,500 | ₩-0.6bn | +₩0.3bn | +₩0.4bn |
| 2026-09-09 | ₩494,500 | +₩1.9bn | +₩11.0bn | ₩-13.2bn |
| 2026-09-08 | ₩471,000 | ₩-9.3bn | ₩-2.2bn | +₩11.0bn |
| 2026-09-07 | ₩475,500 | ₩-0.9bn | ₩-5.3bn | +₩5.9bn |
| 2026-09-04 | ₩473,500 | +₩4.8bn | ₩-4.7bn | ₩-0.1bn |
| 2026-09-03 | ₩460,500 | +₩18.2bn | ₩-17.2bn | ₩-0.6bn |
| 2026-09-02 | ₩474,000 | +₩18.0bn | ₩-16.5bn | ₩-4.0bn |
| 2026-09-01 | ₩492,000 | +₩3.6bn | +₩0.8bn | ₩-4.2bn |
| 2026-08-31 | ₩492,500 | +₩9.9bn | ₩-2.9bn | ₩-6.2bn |
| 2026-08-28 | ₩509,000 | ₩-8.8bn | +₩14.7bn | ₩-6.9bn |
| 2026-08-27 | ₩504,000 | ₩-8.5bn | ₩-5.2bn | +₩13.9bn |
| 2026-08-26 | ₩530,000 | ₩-26.5bn | +₩30.3bn | ₩-2.9bn |
| 2026-08-25 | ₩501,000 | ₩-43.6bn | +₩45.4bn | +₩13.2bn |
| 2026-08-24 | ₩540,000 | ₩-49.9bn | +₩30.8bn | ₩-1.4bn |
| 2026-08-21 | ₩415,500 | ₩-8.2bn | +₩23.2bn | ₩-14.3bn |
| 2026-08-20 | ₩399,000 | ₩-3.7bn | +₩2.7bn | +₩1.1bn |
| 2026-08-19 | ₩388,500 | ₩-0.7bn | +₩1.4bn | ₩-0.8bn |
| 2026-08-18 | ₩392,000 | ₩-2.7bn | +₩3.8bn | ₩-1.2bn |
| 2026-08-14 | ₩398,500 | +₩3.0bn | ₩-3.2bn | +₩0.0bn |
| 2026-08-13 | ₩398,500 | +₩4.6bn | ₩-3.0bn | ₩-1.7bn |
| 2026-08-12 | ₩396,000 | ₩-1.5bn | ₩-6.1bn | +₩7.7bn |
| 2026-08-11 | ₩413,000 | ₩-4.5bn | +₩5.4bn | ₩-1.4bn |
| 2026-08-10 | ₩407,500 | +₩1.3bn | +₩2.6bn | ₩-3.2bn |
| 2026-08-07 | ₩392,500 | ₩-5.4bn | +₩5.6bn | ₩-0.1bn |
| 2026-08-06 | ₩391,000 | ₩-5.0bn | +₩7.7bn | ₩-2.6bn |
| 2026-08-05 | ₩380,000 | ₩-2.0bn | +₩3.8bn | ₩-1.9bn |
| 2026-08-04 | ₩378,000 | +₩3.9bn | +₩5.1bn | ₩-8.7bn |
| 2026-08-03 | ₩345,500 | ₩-5.1bn | +₩8.1bn | ₩-2.8bn |
| 2026-07-31 | ₩333,500 | +₩10.8bn | ₩-1.0bn | ₩-9.8bn |
| 2026-07-30 | ₩311,500 | +₩4.0bn | ₩-0.3bn | ₩-3.7bn |
| 2026-07-29 | ₩322,000 | +₩19.2bn | ₩-26.3bn | +₩6.9bn |
| 2026-07-28 | ₩374,500 | ₩-1.9bn | +₩3.3bn | ₩-1.4bn |
| 2026-07-27 | ₩390,500 | ₩-2.0bn | +₩2.5bn | ₩-0.6bn |
| 2026-07-24 | ₩392,000 | ₩-0.4bn | +₩7.2bn | ₩-6.6bn |
| 2026-07-23 | ₩389,000 | +₩6.7bn | ₩-0.4bn | ₩-6.2bn |
| 2026-07-22 | ₩369,000 | +₩8.1bn | ₩-7.0bn | ₩-1.2bn |
| 2026-07-21 | ₩372,500 | +₩0.2bn | +₩3.5bn | ₩-3.6bn |
| 2026-07-20 | ₩372,000 | +₩0.8bn | +₩1.1bn | ₩-2.1bn |
| 2026-07-16 | ₩386,000 | ₩-0.5bn | ₩-0.3bn | +₩0.4bn |
| 2026-07-15 | ₩384,500 | +₩17.1bn | +₩1.3bn | ₩-18.4bn |
| 2026-07-14 | ₩356,500 | +₩10.9bn | ₩-8.9bn | +₩3.2bn |
| 2026-07-13 | ₩381,500 | +₩14.0bn | +₩0.3bn | ₩-14.4bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | +₩15.8bn | +$12M | ₩-3.7bn | ₩-12.0bn |
| 5 days | ₩-58.6bn | $-44M | ₩-2.2bn | +₩59.6bn |
| 20 days | ₩-116.3bn | $-87M | +₩128.3bn | ₩-10.4bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Hanmi Pharm stock?
Over the last 5 sessions foreign investors net sold ₩58.6bn ($44M) of Hanmi Pharm; over 60 sessions they net sold ₩160.5bn ($120M); since Jan 1, 2026 they net sold ₩6.7bn ($5M). Over 20 sessions the stock is the 23rd largest foreign net sale among 832 KOSPI stocks.
How much of Hanmi Pharm do foreign investors own?
Foreign investors own 11.66% of Hanmi Pharm's shares as of Oct 13, 2026, versus 13.64% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net bought ₩128.3bn ($96M) and retail investors net sold ₩10.4bn ($8M) of Hanmi Pharm. Institutions are on the other side of foreign selling.
Is Hanmi Pharm listed on KOSPI or KOSDAQ?
Hanmi Pharm (한미약품) trades on KOSPI under KRX code 128940 in the Biotech & Pharma group, with a market capitalization of ₩6T ($4.4B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | ₩1.5T ($1.1B) | – | ₩221bn ($166M) | ₩165bn ($124M) |
| 2024 | ₩1.5T ($1.1B) | +0.30% | ₩216bn ($162M) | ₩140bn ($105M) |
| 2025 | ₩1.5T ($1.2B) | +3.50% | ₩258bn ($193M) | ₩187bn ($140M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.